Analysts think ELVN stock price could increase by 107%
Jun 13, 2025, 11:25 AM
13.94%
What does ELVN do
Enliven Therapeutics, a clinical stage precision oncology company based in Boulder, Colorado, went public on March 12, 2020. It is developing ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2 mutations.
9 analysts think ELVN stock price will increase by 107.16%. The current median analyst target is $40.80 compared to a current stock price of $19.70. The lowest analysts target is $27.27 and the highest analyst target is $47.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.